Rate My Professor Peter Lay

Lay's research centers on bioinorganic chemistry, elucidating the mechanisms, efficacy, and toxicities of metal-based drugs including ruthenium and gallium anti-cancer agents, vanadium and chromium(III) anti-diabetic compounds, copper anti-inflammatory drugs, and carcinogens like chromium(VI) and nickel. He pioneered biospectroscopic applications of synchrotron X-ray absorption spectroscopy, vibrational spectroscopy, and imaging to investigate biochemical changes in cardiovascular diseases, cerebral malaria, meningitis, and cancers. His scholarship has garnered over 19,430 citations. Key publications encompass 'The decamethylferrocenium/decamethylferrocene redox couple: a superior redox standard...' (Noviandri et al., 1999, Journal of Physical Chemistry B), 'Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized' (Weder et al., 2002, Coordination Chemistry Reviews), 'Mechanistic studies of relevance to the biological activities of chromium' (Levina & Lay, 2005, Coordination Chemistry Reviews), and 'Speciation of metal drugs, supplements and toxins in media and bodily fluids controls in vitro activities' (Levina et al., 2017, Coordination Chemistry Reviews). Honors include the Rennie Memorial Medal (1987), Edgeworth David Medal (1988), Burrows Award (2001), H.G. Smith Memorial Medal (2005), Fellowship of the Australian Academy of Science (2007), David Craig Medal (2013), Fellowship of the Royal Society of NSW (2016), and ANSTO Australian Synchrotron Lifetime Contribution Award (2020). He advanced commercialization of metal anti-inflammatory drugs for veterinary applications via Medical Therapies, floated on the Australian Stock Exchange.